3 September 2018

Dendritic cells (DCs) are a rare type of immune cells that scan the body for infectious invaders and cancers. Once identified, DCs train the immune system to destroy these attackers; keeping us healthy. Because of these skills, DCs are currently in the focus of anti-cancer vaccine research.

The messenger molecule type I IFN, which is produced in large quantities by the specialized plasmacytoid DCs, plays a central role in the initiation of immune responses. Understanding how pDCs control the production of type I IFN is key to more effective treatment, but our knowledge of the cellular mechanisms is incomplete.

Researchers from Radboudumc and Eindhoven University of Technology developed a high-throughput nano lab to shed light on this process. Last week, their findings were published in Nature Communications.

Using their device, the researchers around Florian Wimmers (Radboudumc, Stanford University) tested thousands of single pDCs for their ability to produce type I IFN. Remarkably, they discovered that only a tiny subset of single pDCs produces type I IFN. When these cells were mixed with other pDCs, crosstalk between individual cells within the population led to a boost in activity. The results of the team around Wimmers that was supervised by Jurjen Tel (TUE) and Jolanda de Vries (Radboudumc) will help to design better cancer treatments. Interventions that target pDCs inside the body should consider that not all pDCs are the same and that the local density of pDCs is an important indicator of their activity.The nano lab that the team used for this analysis was developed in collaboration with Wilhelm Huck (Radboud University) and Carl Figdor (Radboudumc). The device generates millions of tiny droplets, each containing a single cell. Researchers study the behavior of the captured cells at high-throughput to better understand cell-cell variability and the fundamental rules of cellular communication.

Related news items

Register for Phd courses via gROW What does this mean for you?

2 July 2020

From now on you can arrange everything related to the general RU PhD courses via gROW. Because of this there will be some changes in the registration! What does this mean for you?

read more

Experts on metabolic diseases still an unknown major problem...

1 July 2020

Six Dutch UMCs and a patient association contribute to treating and solving this major, often unknown, problem. Timely detection of metabolic diseases is vital. Therefore, the consortium “United for Metabolic Diseases” has started a media campaign.

read more

Radboud Pluim for Lionne Ekers ambassador for the RIMLS institute

30 June 2020

Lionne Ekers received the Radboudpluim for her special merits for the Radboudumc. She is a born ambassador for our Institute.

read more

Stefan Listl member Lancet Commission on Oral Health

29 June 2020

In recognition of the global public health importance, woeful neglect of oral diseases, and the need for a broader understanding and commitment to global oral health within medicine and global health agendas, The Lancet recently established a Commission on Oral Health.

read more

Trained immunity: a tool for reducing susceptibility to and the severity of SARS-CoV-2 infection

29 June 2020

In a review in Cell Mihai Netea, Frank van de Veerdonk, Reinout van Crevel and Jorge Dominguez Andres propose that induction of trained immunity by whole-microorganism vaccines may represent an important tool for reducing susceptibility to and severity of SARS-CoV-2.

read more

Towards an AI diagnosis like the doctor's

25 June 2020

How can we make ‘lazy’ artificial intelligence more transparent and relevant to the clinic?

read more